News Chiesi fills permanent CEO role with Flagship's Khougazian Chiesi has named Flagship's David Khougazian as its new permanent chief executive, following the departure of Giuseppe Accogli earlier this year.
News UK postcode lottery ends for 'life-changing' cystinosis drug Patients in England with rare disease cystinosis will soon be able to access a drug that has been available in other UK nations for up to three years
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Patients Sponsored Protecting continuity of care through sustainable respirator... More attention is being paid to how care can be delivered in ways that maintain continuity for patients while also being environmentally responsible.
News England poised to roll out drug for rare eye disease LHON Patients in England with rare eye disorder LHON will finally get access to a Chiesi drug that has been available in the rest of the UK for years.
Digital Sponsored Digital health technologies and rare diseases: Enhancing the... This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an honorarium for his participation and contribution to this webinar.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.